Volume | 1,977,303 |
|
|||||
News | - | ||||||
Day High | 5.21 | Low High |
|||||
Day Low | 4.58 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Annexon Inc | ANNX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
5.14 | 4.58 | 5.21 | 4.585 | 5.115 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
16,440 | 1,977,303 | US$ 4.90 | US$ 9,683,766 | - | 1.57 - 8.40 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
17:42:29 | 18 | US$ 4.59 | USD |
Annexon (ANNX) Options Flow Summary
Annexon Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
243.83M | 53.24M | - | 0 | -134.24M | -2.52 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Annexon News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ANNX Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 6.07 | 6.56 | 4.58 | 5.78 | 1,182,658 | -1.62 | -26.69% |
1 Month | 6.01 | 8.40 | 4.58 | 6.63 | 2,049,918 | -1.56 | -25.96% |
3 Months | 4.83 | 8.40 | 3.86 | 6.01 | 1,585,346 | -0.38 | -7.87% |
6 Months | 1.82 | 8.40 | 1.67 | 5.14 | 1,183,527 | 2.63 | 144.51% |
1 Year | 4.90 | 8.40 | 1.57 | 4.44 | 931,473 | -0.45 | -9.18% |
3 Years | 23.14 | 24.85 | 1.57 | 5.90 | 529,224 | -18.69 | -80.77% |
5 Years | 16.8635 | 38.01 | 1.57 | 7.39 | 459,231 | -12.41 | -73.61% |
Annexon Description
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Annexon's product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; and ANX009, for systemic autoimmune diseases. |